BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)-Results from the ETOP 13-18 trial

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2024
This article has no abstract
Epistemonikos ID: 18aec49293c8f640ea39201791138e9b4a89edad
First added on: Nov 24, 2025